Find key clinical documentation and medical coding information for neutropenic fever. This resource offers guidance on neutropenia diagnosis, febrile neutropenia management, and ICD-10 codes for neutropenic fever. Learn about appropriate documentation for neutropenia and fever, including severity grading and treatment protocols. Explore best practices for healthcare professionals related to neutropenic sepsis and its implications for patient care and coding accuracy.
Also known as
Neutropenia
Abnormally low count of neutrophils in the blood.
General symptoms and signs
Includes fever as a symptom (R50.9).
Aplastic and other anemias
Can sometimes cause neutropenia and fever.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is fever documented (100.4F/38C or higher)?
When to use each related code
| Description |
|---|
| Fever in neutropenic patient |
| Febrile neutropenia |
| Neutropenia |
Coding neutropenic fever without specifying the underlying cause (e.g., chemotherapy, disease) leads to inaccurate severity and reimbursement.
Lack of clear fever documentation (temperature, time, method) can cause coding and billing errors, impacting quality metrics and revenue.
Overlapping symptoms may lead to incorrect coding of neutropenic sepsis instead of neutropenic fever, resulting in upcoding and compliance risks.
Q: What is the most effective empiric antibiotic therapy for neutropenic fever in adult cancer patients with high-risk features?
A: For adult cancer patients with neutropenic fever and high-risk features (e.g., profound neutropenia expected to last >7 days, hemodynamic instability, pneumonia, or other serious infections), current guidelines recommend empiric broad-spectrum antibiotic therapy covering both gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa. Common choices include an antipseudomonal beta-lactam (e.g., cefepime, meropenem, piperacillin-tazobactam) combined with an aminoglycoside (e.g., amikacin, gentamicin, tobramycin) or a fluoroquinolone with antipseudomonal activity (e.g., ciprofloxacin, levofloxacin). Vancomycin or other agents with MRSA activity should be added if there is a clinical suspicion of catheter-related infection, skin/soft tissue infection, or pneumonia. The specific choice of antibiotics should be guided by local resistance patterns and institutional guidelines. Explore how risk stratification can further refine antibiotic choices for neutropenic fever. Consider implementing a rapid diagnostic testing strategy to help guide de-escalation of antibiotics once culture results are available.
Q: How do I differentiate between febrile neutropenia and other causes of fever in a patient undergoing chemotherapy?
A: Differentiating febrile neutropenia from other fever sources in chemotherapy patients requires a comprehensive approach. Firstly, establish the presence of neutropenia (absolute neutrophil count <500/mm3 or <1000/mm3 with predicted decline to <500/mm3) along with a single oral temperature of 38.3°C (101°F) or a sustained temperature of 38.0°C (100.4°F) for over an hour. Consider common causes of infection in this population, such as mucositis, pneumonia, urinary tract infections, and skin/soft-tissue infections. A thorough physical exam focusing on potential infection sites (including central venous catheter sites) is crucial. Blood cultures (both peripheral and from central lines if applicable), urine cultures, and other relevant cultures based on clinical suspicion should be obtained. Chest X-ray and other imaging studies may be indicated based on clinical presentation. While infections are the most common cause of fever in neutropenic patients, non-infectious causes like drug reactions, tumor lysis syndrome, and graft-versus-host disease (in transplant recipients) should also be considered. Learn more about the diagnostic workup for febrile neutropenia in different clinical scenarios.
Patient presents with neutropenic fever, defined as a single oral temperature of 38.3 degrees Celsius or higher or a temperature of 38.0 degrees Celsius sustained for one hour, in the setting of neutropenia. Absolute neutrophil count (ANC) is documented as (insert value), classifying the neutropenia as (mild, moderate, severe, profound). The patient's current symptoms include (list symptoms e.g., chills, fatigue, malaise, cough, dyspnea, abdominal pain, diarrhea, urinary symptoms, etc.). Relevant medical history includes (list relevant diagnoses e.g., hematologic malignancy, chemotherapy regimen, recent bone marrow transplant, immunosuppressive therapy, etc.). Physical examination reveals (document vital signs, including temperature, heart rate, respiratory rate, blood pressure, and oxygen saturation; note pertinent positive and negative findings related to potential sources of infection, e.g., skin assessment for rashes or lesions, lung auscultation, abdominal examination). Given the concern for febrile neutropenia, blood cultures have been obtained from two peripheral sites. A complete blood count (CBC) with differential, comprehensive metabolic panel (CMP), and urinalysis have been ordered. Based on the patient's clinical presentation and risk stratification, empiric broad-spectrum antibiotics (specify antibiotic regimen, e.g., cefepime, piperacillin-tazobactam, meropenem) have been initiated. The patient will be closely monitored for clinical response to antibiotics and any signs of complications, including sepsis, septic shock, and multi-organ dysfunction syndrome. Further investigations will be guided by the patient's clinical course and culture results. Differential diagnosis includes infection (bacterial, fungal, viral), drug-induced fever, and underlying disease process. The patient's risk factors for infection are documented, and appropriate infection prevention measures have been implemented. This case represents a serious medical condition requiring inpatient management and close monitoring.